JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB141143

Dofetilide, hERG K+ channel blocker

Be the first to review this product! Submit a review

|

(0 Publication)

MW 441.6 Da, Purity >98%. Potent and selective hERG K+ channel blocker. Selectively blocks the rapid component of the delayed rectifier outward potassium current. Class III antiarrhythmic agent. Increases the atrial refractory period *in vivo.* Orally active.

View Alternative Names

Eag-related protein 1, Ether a go go related potassium channel protein, Ether-a-go-go-related gene potassium channel 1, Ether-a-go-go-related protein 1, H-ERG, KCNH2_HUMAN, Kv11.1, LQT 2, Potassium channel HERG, Potassium voltage gated channel subfamily H (eag related) member 2, Potassium voltage-gated channel subfamily H member 2, SQT1, Voltage gated potassium channel, subfamily H, member 2, Voltage-gated potassium channel subunit Kv11.1, eag homolog, hERG-1

1 Images
Chemical Structure - Dofetilide, hERG K+ channel blocker (AB141143)
  • Chemical Structure

Lab

Chemical Structure - Dofetilide, hERG K+ channel blocker (AB141143)

2D chemical structure image of ab141143, Dofetilide, hERG K+ channel blocker

Key facts

CAS number

115256-11-6

Purity

>98%

Form

Solid

form

Molecular weight

441.6 Da

Molecular formula

C<sub>1</sub><sub>9</sub>H<sub>2</sub><sub>7</sub>N<sub>3</sub>O<sub>5</sub>S<sub>2</sub>

PubChem

71329

Nature

Synthetic

Solubility

Soluble in DMSO to 50 mM

Biochemical name

Dofetilide

Biological description

Potent and selective hERG K+ channel blocker. Selectively blocks the rapid component of the delayed rectifier outward potassium current. Class III antiarrhythmic agent. Increases the atrial refractory period *in vivo.* Orally active.

Canonical smiles

CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C

InChi

InChI=1S/C19H27N3O5S2/c1-22(13-12-16-4-6-17(7-5-16)20-28(2,23)24)14-15-27-19-10-8-18(9-11-19)21-29(3,25)26/h4-11,20-21H,12-15H2,1-3H3

InChiKey

IXTMWRCNAAVVAI-UHFFFAOYSA-N

IUPAC Name

N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
Ambient
Appropriate long-term storage conditions
Ambient
Storage information
The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The human ether-à-go-go-related gene (hERG) encodes a protein known as Kv11.1 which is a voltage-gated potassium channel. This channel plays an important mechanical role in cardiac repolarization by facilitating the movement of potassium ions out of cardiomyocytes. Kv11.1 consists of a tetrameric assembly of six transmembrane segments contributing to its function as a channel. hERG's expression is high in cardiac tissue but also found in the nervous system and other tissues. The molecular weight of the Kv11.1 protein is approximately 137 kDa. Common hERG channel blockers include compounds like dofetilide and bedaquiline which are significant for studies of drug interactions.
Biological function summary

The proper functioning of Kv11.1 channels is essential in maintaining the electrical stability of cardiac cells. Kv11.1 is an integral part of the cardiac action potential complex contributing heavily to the IKr (rapid component of the delayed rectifier potassium current) in the heart. Its function aids in the prevention of arrhythmias by ensuring timely repolarization. The channel also appears in specific non-cardiac cells influencing cellular excitability and signaling but to lesser extents. hERG's role in the physiology of these cells highlights its involvement in maintaining normal cell electrophysiology.

Pathways

Kv11.1's function plays a central role in electrophysiological pathways that influence cardiac action potential duration and repolarization. One important pathway is the cardiac conduction system where the hERG channels modulate the cardiac cycle alongside other channels like beta 1 and beta 2 adrenergic receptors. These pathways are intertwined with cellular functions and control heart rate and rhythm demonstrating hERG's critical contribution to heart physiology. Any dysfunction in this pathway can lead to severe cardiac conditions.

The dysfunction of hERG channels can result in severe cardiac conditions like Long QT Syndrome and Torsades de Pointes. These disorders arise from prolonged cardiac repolarization which can trigger life-threatening arrhythmias. Analogs such as fluphenazine and dofetilide interact with hERG providing therapeutic applications and potential side effects relating to cardiac health. Alterations in hERG's function therefore require careful modulation to prevent detrimental effects on cardiac activity. The understanding of hERG-related pathophysiology connects it to broader themes in cardiology and pharmacology.

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com